Sage’s recent trial failure adds pressure to its two-drug Biogen collab

One of two drugs being developed by Biogen and Sage Therapeutics failed a mid-stage study, pushing both companies to announce they would not be moving forward with further development. The $1.5 billion partnership now hinges on an approved drug that has already faced challenges.